Affective spectrum disorders: how to recognize and treat depression

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Medicine

Background:

• Depression is frequently undiagnosed, and patient discontinuation of pharmacotherapy increases relapse risk.
• The average age of depression onset is the late twenties, though it can occur at any age.
• Various factors, including medications, substance abuse, and medical conditions, can cause or mimic depression.

Purpose of the Study:

• To provide clinicians with tools for recognizing depression.
• To outline considerations for selecting antidepressant pharmacotherapy.
• To review the side effect profiles and risks associated with different antidepressant classes.

Main Methods:

• Review of common diagnostic challenges and acronyms for depression recognition.
• Analysis of factors influencing antidepressant selection, including patient history, side effects, and suicide risk.
• Comparison of adverse effect profiles for traditional (tricyclic antidepressants, monoamine oxidase inhibitors) and newer antidepressant classes (selective serotonin reuptake inhibitors).

Main Results:

• Selective serotonin reuptake inhibitors (SSRIs) generally present more tolerable side effects compared to older antidepressants.
• Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) carry risks such as anticholinergic effects, orthostasis, and overdose lethality.
• SSRIs are frequently the first-line pharmacotherapy choice for depression.

Conclusions:

• Effective recognition and management of depression are essential to prevent relapse.
• Antidepressant choice requires careful consideration of efficacy, side effect profiles, and patient-specific factors.
• SSRIs represent a generally preferred first-line treatment option due to their safety and tolerability profile.